Результаты поиска - Jan Philipp Bewersdorf

Отмена результатов
  1. 1
    Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments?

    Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments? по Jan Philipp Bewersdorf, Amer M. Zeidan

    Опубликовано 2020
    Полный текст Полный текст
    Revisão
    Добавить в Избранное
    Сохранить в:
  2. 2
    Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic

    Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic по Jan Philipp Bewersdorf, Omar Abdel‐Wahab

    Опубликовано 2022
    Полный текст Полный текст
    Revisão
    Добавить в Избранное
    Сохранить в:
  3. 3
    BiTEs, DARTS, BiKEs and TriKEs—Are Antibody Based Therapies Changing the Future Treatment of AML?

    BiTEs, DARTS, BiKEs and TriKEs—Are Antibody Based Therapies Changing the Future Treatment of AML? по Cecily Allen, Amer M. Zeidan, Jan Philipp Bewersdorf

    Опубликовано 2021
    Полный текст Полный текст
    Revisão
    Добавить в Избранное
    Сохранить в:
  4. 4
    Epigenetic therapy combinations in acute myeloid leukemia: what are the options?

    Epigenetic therapy combinations in acute myeloid leukemia: what are the options? по Jan Philipp Bewersdorf, Rory M. Shallis, Maximilian Stahl, Amer M. Zeidan

    Опубликовано 2019
    Полный текст Полный текст
    Revisão
    Добавить в Избранное
    Сохранить в:
  5. 5
    Leukapheresis for the management of hyperleukocytosis in acute myeloid leukemia—A systematic review and meta‐analysis

    Leukapheresis for the management of hyperleukocytosis in acute myeloid leukemia—A systematic review and meta‐analysis по Jan Philipp Bewersdorf, Smith Giri, Martin S. Tallman, Amer M. Zeidan, Maximilian Stahl

    Опубликовано 2020
    Полный текст
    Revisão
    Добавить в Избранное
    Сохранить в:
  6. 6
    <p>Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis</p>

    <p>Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis</p> по Jan Philipp Bewersdorf, Sara Mohamed Jaszczur, Salma Afifi, Jennifer Zhao, Amer M. Zeidan

    Опубликовано 2019
    Полный текст Полный текст
    Revisão
    Добавить в Избранное
    Сохранить в:
  7. 7
    A review of FLT3 inhibitors in acute myeloid leukemia

    A review of FLT3 inhibitors in acute myeloid leukemia по Jennifer Zhao, Sonal Agarwal, Hiba Ahmad, Kejal Amin, Jan Philipp Bewersdorf, Amer M. Zeidan

    Опубликовано 2021
    Полный текст
    Revisão
    Добавить в Избранное
    Сохранить в:
  8. 8
    Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis

    Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and... по Jan Philipp Bewersdorf, Smith Giri, Rong Wang, Robert T. Williams, Martin S. Tallman, Amer M. Zeidan, Maximilian Stahl

    Опубликовано 2020
    Полный текст Полный текст
    Revisão
    Добавить в Избранное
    Сохранить в:
  9. 9
    Interferon alpha therapy in essential thrombocythemia and polycythemia vera—a systematic review and meta-analysis

    Interferon alpha therapy in essential thrombocythemia and polycythemia vera—a systematic review and meta-analysis по Jan Philipp Bewersdorf, Smith Giri, Rong Wang, Nikolai A. Podoltsev, Robert T. Williams, Martin S. Tallman, Raajit K. Rampal, Amer M. Zeidan, Maximilian Stahl

    Опубликовано 2020
    Полный текст
    Revisão
    Добавить в Избранное
    Сохранить в:
  10. 10
    Calcium Influx through Plasma-Membrane Nanoruptures Drives Axon Degeneration in a Model of Multiple Sclerosis

    Calcium Influx through Plasma-Membrane Nanoruptures Drives Axon Degeneration in a Model of Multiple Sclerosis по Maarten E. Witte, Adrian-Minh Schumacher, Christoph Mahler, Jan Philipp Bewersdorf, Jonas Lehmitz, Alexander Scheiter, Paula Sánchez, Philip R. Williams, Oliver Griesbeck, Ronald Naumann, Thomas Misgeld, Martin Kerschensteiner

    Опубликовано 2019
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  11. 11
    Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States

    Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States по Amer M. Zeidan, Rong Wang, Xiaoyi Wang, Rory M. Shallis, Nikolai A. Podoltsev, Jan Philipp Bewersdorf, Scott F. Huntington, Natalia Neparidze, Smith Giri, Steven D. Gore, Amy J. Davidoff, Xiaomei Ma

    Опубликовано 2020
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  12. 12
    Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes

    Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes по Amer M. Zeidan, Daniel J. DeAngelo, Jeanne Palmer, Christopher S. Seet, Martin S. Tallman, Xin Wei, Heather K. Raymon, Priya Sriraman, Stephan Kopytek, Jan Philipp Bewersdorf, Michael R. Burgess, Kristen Hege, Wendy Stock

    Опубликовано 2022
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  13. 13
    Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States

    Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States по Amer M. Zeidan, Nikolai A. Podoltsev, Xiaoyi Wang, Chi Zhang, Jan Philipp Bewersdorf, Rory M. Shallis, Scott F. Huntington, Natalia Neparidze, Smith Giri, Steven D. Gore, Amy J. Davidoff, Xiaomei Ma, Rong Wang

    Опубликовано 2020
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  14. 14
    E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial

    E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial по Jan Philipp Bewersdorf, Maximilian Stahl, Justin Taylor, Xiaoli Mi, Namrata Sonia Chandhok, Justin M. Watts, Andriy Derkach, Mateusz Wysocki, Sydney X. Lu, Jessie Bourcier, Simon J. Hogg, Jahan Rahman, Sana Chaudhry, Tulasigeri M. Totiger, Omar Abdel‐Wahab, Eytan M. Stein

    Опубликовано 2023
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  15. 15
    Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

    Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Mye... по Talha Badar, Ehab Atallah, Rory M. Shallis, Antoine N. Saliba, Anand Patel, Jan Philipp Bewersdorf, Justin Grenet, Maximilian Stahl, Adam DuVall, Madelyn Burkart, Neil Palmisiano, Danielle Bradshaw, Michal Kubiak, Shira Dinner, Aaron D. Goldberg, Yasmin Abaza, Guru Subramanian Guru Murthy, Vamsi Kota, Mark R. Litzow

    Опубликовано 2023
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  16. 16
    Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

    Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the C... по Talha Badar, Ahmad Nanaa, Ehab Atallah, Rory M. Shallis, Sacchi de Camargo Correia Guilherme, Aaron D. Goldberg, Antoine N. Saliba, Anand Patel, Jan Philipp Bewersdorf, Adam DuVall, Danielle Bradshaw, Yasmin Abaza, Guru Subramanian Guru Murthy, Neil Palmisiano, Amer M. Zeidan, Vamsi Kota, Mark R. Litzow

    Опубликовано 2024
    Полный текст Полный текст
    Carta
    Добавить в Избранное
    Сохранить в:
  17. 17
    Outcomes of <scp><i>TP53</i></scp>‐mutated <scp>AML</scp> with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival

    Outcomes of <scp><i>TP53</i></scp>‐mutated <scp>AML</scp> with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival по Talha Badar, Ehab Atallah, Rory M. Shallis, Aaron D. Goldberg, Anand Patel, Yasmin Abaza, Jan Philipp Bewersdorf, Antoine N. Saliba, Guilherme Sacchi de Camargo Correia, Guru Subramanian Guru Murthy, Adam DuVall, Madelyn Burkart, Maximilian Stahl, Yuanhang Liu, Shira Dinner, Neil Palmisiano, Mark R. Litzow, James M. Foran

    Опубликовано 2022
    Полный текст Полный текст
    Carta
    Добавить в Избранное
    Сохранить в:
  18. 18
    Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies

    Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies по Jan Philipp Bewersdorf, Xiaoli Mi, Bin Lü, Andrew Kuykendall, David A. Sallman, Manish R. Patel, Don A. Stevens, Alexander Philipovskiy, Grerk Sutamtewagul, Lucia Masárová, Gina Keiffer, Amit Verma, Neha Bhagwat, Min Wang, Andrew S. Moore, Joseph Rager, Diane Heiser, Sunhee Ro, Wan‐Jen Hong, Omar Abdel‐Wahab, Eytan M. Stein

    Опубликовано 2025
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  19. 19
    Synthetic introns enable splicing factor mutation-dependent targeting of cancer cells

    Synthetic introns enable splicing factor mutation-dependent targeting of cancer cells по Khrystyna North, Salima Benbarche, Bo Liu, Joseph Pangallo, Sisi Chen, Maximilian Stahl, Jan Philipp Bewersdorf, Robert Stanley, Caroline Erickson, Hana Cho, Jose Mario Bello Pineda, James D. Thomas, Jacob T. Polaski, Andrea E. Belleville, Austin M. Gabel, Dylan B. Udy, Olivier Humbert, Hans‐Peter Kiem, Omar Abdel‐Wahab, Robert K. Bradley

    Опубликовано 2022
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  20. 20
    Prognostic impact of ‘multi-hit’ &lt;i&gt;versus&lt;/i&gt; ‘single hit’ &lt;i&gt;TP53&lt;/i&gt; alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases

    Prognostic impact of ‘multi-hit’ &lt;i&gt;versus&lt;/i&gt; ‘single hit’ &lt;i&gt;TP53&lt;/i&gt; alteration in patients with acute myeloid leukemia: results from the Consortium on M... по Talha Badar, Ahmad Nanaa, Ehab Atallah, Rory M. Shallis, Emily C. Craver, Zhuo Li, Aaron D. Goldberg, Antoine N. Saliba, Anand Patel, Jan Philipp Bewersdorf, Adam DuVall, Madelyn Burkart, Danielle Bradshaw, Yasmin Abaza, Maximilian Stahl, Neil Palmisiano, Guru Subramanian Guru Murthy, Amer M. Zeidan, Vamsi Kota, Mrinal M. Patnaik, Mark R. Litzow

    Опубликовано 2024
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:

Инструменты поиска: